Spots Global Cancer Trial Database for rrmm
Every month we try and update this database with for rrmm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) | NCT02684617 | rrCLL rrMM rrDLBCL | pembrolizumab dinaciclib | 18 Years - | Merck Sharp & Dohme LLC | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | NCT06215118 | Multiple Myelom... | Elranatamab Iberdomide | 18 Years - | Pfizer | |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | NCT06106945 | Multiple Myelom... | AZD0305 | 18 Years - | AstraZeneca | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | NCT04177823 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT05519085 | Relapsed or Ref... | mezigdomide Pomalidomide Bortezomib Dexamethasone | 18 Years - | Celgene | |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | NCT05064358 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | NCT03110562 | Multiple Myelom... | Selinexor Bortezomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | NCT02046070 | Multiple Myelom... | Cyclophosphamid... Ixazomib Dexamethasone | 18 Years - | Takeda | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06297226 | Multiple Myelom... | BMS-986393 | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | NCT03136653 | Multiple Myelom... | MP0250 plus BOR... | 18 Years - | Molecular Partners AG | |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) | NCT02684617 | rrCLL rrMM rrDLBCL | pembrolizumab dinaciclib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | NCT05651932 | Multiple Myelom... Myeloma Myeloma Multipl... | KTX-1001 | 18 Years - | K36 Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
